A Naturally Occurring C-terminal Fragment of the Prion Protein (PrP) Delays Disease and Acts as a Dominant-negative Inhibitor of PrPSc Formation*

Background: C1 is the main physiological cleavage fragment of PrP, but its role in disease is unknown. Results: C1 is not toxic when expressed in mice and delays the onset of disease and PrPSc formation when co-expressed with WT PrP. Conclusion: C1 is a dominant-negative inhibitor of PrPSc formation. Significance: Modulation of C1 cleavage may represent a therapeutic strategy for combating PrPSc infection. The cellular prion protein (PrPC) undergoes constitutive proteolytic cleavage between residues 111/112 to yield a soluble N-terminal fragment (N1) and a membrane-anchored C-terminal fragment (C1). The C1 fragment represents the major proteolytic fragment of PrPC in brain and several cell types. To explore the role of C1 in prion disease, we generated Tg(C1) transgenic mice expressing this fragment (PrP(Δ23–111)) in the presence and absence of endogenous PrP. In contrast to several other N-terminally deleted forms of PrP, the C1 fragment does not cause a spontaneous neurological disease in the absence of endogenous PrP. Tg(C1) mice inoculated with scrapie prions remain healthy and do not accumulate protease-resistant PrP, demonstrating that C1 is not a substrate for conversion to PrPSc (the disease-associated isoform). Interestingly, Tg(C1) mice co-expressing C1 along with wild-type PrP (either endogenous or encoded by a second transgene) become ill after scrapie inoculation, but with a dramatically delayed time course compared with mice lacking C1. In addition, accumulation of PrPSc was markedly slowed in these animals. Similar effects were produced by a shorter C-terminal fragment of PrP(Δ23–134). These results demonstrate that C1 acts as dominant-negative inhibitor of PrPSc formation and accumulation of neurotoxic forms of PrP. Thus, C1, a naturally occurring fragment of PrPC, might play a modulatory role during the course of prion diseases. In addition, enhancing production of C1, or exogenously administering this fragment, represents a potential therapeutic strategy for the treatment of prion diseases.

[1]  D. Harris,et al.  A Nine Amino Acid Domain Is Essential for Mutant Prion Protein Toxicity , 2011, The Journal of Neuroscience.

[2]  I. Solomon,et al.  An N-terminal Polybasic Domain and Cell Surface Localization Are Required for Mutant Prion Protein Toxicity* , 2011, The Journal of Biological Chemistry.

[3]  J. Collinge,et al.  Prion propagation and toxicity in vivo occur in two distinct mechanistic phases , 2011, Nature.

[4]  I. Solomon,et al.  Neurotoxic Mutants of the Prion Protein Induce Spontaneous Ionic Currents in Cultured Cells* , 2010, The Journal of Biological Chemistry.

[5]  Frank Baumann,et al.  Axonal prion protein is required for peripheral myelin maintenance , 2010, Nature Neuroscience.

[6]  S. Supattapone,et al.  Trans-Dominant Inhibition of Prion Propagation In Vitro Is Not Mediated by an Accessory Cofactor , 2009, PLoS pathogens.

[7]  N. Hooper,et al.  α-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts , 2009, Molecular and Cellular Neuroscience.

[8]  G. Baron,et al.  Specific biarsenical labeling of cell surface proteins allows fluorescent- and biotin-tagging of amyloid precursor protein and prion proteins. , 2009, Molecular biology of the cell.

[9]  D. Selkoe,et al.  Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.

[10]  V. Compan,et al.  Effective Gene Therapy in a Mouse Model of Prion Diseases , 2008, PloS one.

[11]  J. Collinge,et al.  Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease , 2008, Proceedings of the National Academy of Sciences.

[12]  A. Aguzzi,et al.  The prion's elusive reason for being. , 2008, Annual review of neuroscience.

[13]  I. Baskakov,et al.  The dominant‐negative effect of the Q218K variant of the prion protein does not require protein X , 2007, Protein science : a publication of the Protein Society.

[14]  R. Williamson,et al.  Toward Molecular Dissection of PrPC-PrPSc Interactions* , 2007, Journal of Biological Chemistry.

[15]  J. Collinge,et al.  Targeting Cellular Prion Protein Reverses Early Cognitive Deficits and Neurophysiological Dysfunction in Prion-Infected Mice , 2007, Neuron.

[16]  A. Aguzzi,et al.  Lethal recessive myelin toxicity of prion protein lacking its central domain , 2007, The EMBO journal.

[17]  K. Roth,et al.  Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105–125 , 2007, The EMBO journal.

[18]  F. Checler,et al.  The C-terminal Products of Cellular Prion Protein Processing, C1 and C2, Exert Distinct Influence on p53-dependent Staurosporine-induced Caspase-3 Activation* , 2007, Journal of Biological Chemistry.

[19]  Mapping of possible prion protein self-interaction domains using peptide arrays , 2007, BMC Biochemistry.

[20]  F. Checler,et al.  The Disintegrin ADAM9 Indirectly Contributes to the Physiological Processing of Cellular Prion by Modulating ADAM10 Activity* , 2005, Journal of Biological Chemistry.

[21]  J. Hauw,et al.  The N‐terminal cleavage of cellular prion protein in the human brain , 2005, FEBS letters.

[22]  N. Hooper,et al.  Reactive Oxygen Species-mediated β-Cleavage of the Prion Protein in the Cellular Response to Oxidative Stress* , 2005, Journal of Biological Chemistry.

[23]  James A Mastrianni,et al.  The AGAAAAGA Palindrome in PrP Is Required to Generate a Productive PrPSc-PrPC Complex That Leads to Prion Propagation* , 2005, Journal of Biological Chemistry.

[24]  D. Burton,et al.  Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Katamine,et al.  Doppel-induced Purkinje cell death is stoichiometrically abrogated by prion protein. , 2004, Biochemical and biophysical research communications.

[26]  G. Telling,et al.  Calpain-dependent Endoproteolytic Cleavage of PrPSc Modulates Scrapie Prion Propagation* , 2004, Journal of Biological Chemistry.

[27]  N. Hooper,et al.  Dual Mechanisms for Shedding of the Cellular Prion Protein* , 2004, Journal of Biological Chemistry.

[28]  T. Onodera,et al.  Alpha‐ and beta‐ cleavages of the amino‐terminus of the cellular prion protein , 2004, Biology of the cell.

[29]  Sebastian Brandner,et al.  Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis , 2003, Science.

[30]  C. Sunyach,et al.  The mechanism of internalization of glycosylphosphatidylinositol‐anchored prion protein , 2003, The EMBO journal.

[31]  F. Cohen,et al.  Dominant-negative inhibition of prion replication in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Lee,et al.  Endocytic Intermediates Involved with the Intracellular Trafficking of a Fluorescent Cellular Prion Protein* , 2002, The Journal of Biological Chemistry.

[33]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[34]  Richard C. Moore,et al.  Doppel-induced cerebellar degeneration in transgenic mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Strooper,et al.  The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein. , 2001, The Journal of biological chemistry.

[36]  D. Harris,et al.  Prion Diseases: What Is the Neurotoxic Molecule? , 2001, Neurobiology of Disease.

[37]  D. Melton,et al.  Changing a single amino acid in the N‐terminus of murine PrP alters TSE incubation time across three species barriers , 2001, The EMBO journal.

[38]  Pauline M. Rudd,et al.  Antibodies inhibit prion propagation and clear cell cultures of prion infectivity , 2001, Nature.

[39]  M. Enari,et al.  Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Caughey,et al.  Inhibition of Interactions and Interconversions of Prion Protein Isoforms by Peptide Fragments from the C-terminal Folded Domain* , 2001, The Journal of Biological Chemistry.

[41]  A. Aguzzi,et al.  Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain , 2001, The EMBO journal.

[42]  A. Mangé,et al.  Cleavage of the Amino Terminus of the Prion Protein by Reactive Oxygen Species* , 2001, The Journal of Biological Chemistry.

[43]  F. Checler,et al.  Phorbol Ester-regulated Cleavage of Normal Prion Protein in HEK293 Human Cells and Murine Neurons* , 2000, The Journal of Biological Chemistry.

[44]  C. V. Mering,et al.  Prion Protein Devoid of the Octapeptide Repeat Region Restores Susceptibility to Scrapie in PrP Knockout Mice , 2000, Neuron.

[45]  I. Mcconnell,et al.  A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy , 1999, The EMBO journal.

[46]  B. Chesebro,et al.  Species-Independent Inhibition of Abnormal Prion Protein (PrP) Formation by a Peptide Containing a Conserved PrP Sequence , 1999, Journal of Virology.

[47]  B. Caughey,et al.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease‐resistant state , 1999, The EMBO journal.

[48]  B. Ghetti,et al.  Neurological Illness in Transgenic Mice Expressing a Prion Protein with an Insertional Mutation , 1998, Neuron.

[49]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[50]  B. Ghetti,et al.  Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. , 1998, The American journal of pathology.

[51]  Christian von Mering,et al.  Expression of Amino-Terminally Truncated PrP in the Mouse Leading to Ataxia and Specific Cerebellar Lesions , 1998, Cell.

[52]  A. Bürkle,et al.  Overexpression of Nonconvertible PrPcΔ114–121 in Scrapie-Infected Mouse Neuroblastoma Cells Leads to trans-Dominant Inhibition of Wild-Type PrPSc Accumulation , 1998, Journal of Virology.

[53]  F E Cohen,et al.  A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. , 1997, Journal of molecular biology.

[54]  F. Cohen,et al.  Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  F. Cohen,et al.  Heritable disorder resembling neuronal storage disease in mice expressing prion protein with deletion of an α-helix , 1997, Nature Medicine.

[56]  J. Rossier,et al.  Transmission of the BSE Agent to Mice in the Absence of Detectable Abnormal Prion Protein , 1997, Science.

[57]  D L Price,et al.  A vector for expressing foreign genes in the brains and hearts of transgenic mice. , 1996, Genetic analysis : biomolecular engineering.

[58]  T. Noda,et al.  Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene , 1996, Nature.

[59]  A. Aguzzi,et al.  Prion protein (PrP) with amino‐proximal deletions restoring susceptibility of PrP knockout mice to scrapie. , 1996, The EMBO journal.

[60]  P. Lantos,et al.  Transmission of fatal familial insomnia to laboratory animals , 1995, The Lancet.

[61]  D. Teplow,et al.  Truncated Forms of the Human Prion Protein in Normal Brain and in Prion Diseases (*) , 1995, The Journal of Biological Chemistry.

[62]  S. Prusiner,et al.  Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform [published erratum appears in J Cell Biol 1995 Jul;130(2):501] , 1995, The Journal of cell biology.

[63]  S. Prusiner,et al.  Serial transmission in rodents of neurodegeneration from transgenic mice expressing mutant prion protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Harris,et al.  A glycolipid-anchored prion protein is endocytosed via clathrin-coated pits , 1994, The Journal of cell biology.

[65]  R J Fletterick,et al.  Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[66]  P. Roller,et al.  Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. , 1993, The Journal of biological chemistry.

[67]  S. Prusiner,et al.  Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. , 1993, Glycobiology.

[68]  D. Harris,et al.  A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. , 1993, The Journal of biological chemistry.

[69]  B. Chait,et al.  Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. , 1993, Biochemistry.

[70]  S. Prusiner,et al.  Synthesis and trafficking of prion proteins in cultured cells. , 1992, Molecular biology of the cell.

[71]  S. Prusiner,et al.  Spontaneous neurodegeneration in transgenic mice with mutant prion protein , 1990, Science.

[72]  T. Crow,et al.  Prion dementia without characteristic pathology , 1990, The Lancet.

[73]  Stanley B. Prusiner,et al.  Scrapie prion protein contains a phosphatidylinositol glycolipid , 1987, Cell.